Oncolytics Biotech® Begins Enrollment Expansion for GOBLET Anal Cancer Cohort
Successful stage 1 data support expansion, with nearly three times the objective response rate compared to checkpoint inhibitor monotherapy, including complete responses. san diego and Calgary, Alberta, February 14, 2024 /CNW/ — Oncolytic biotechnology® Inc. (NASDAQ: ONCY) (TSX: ONC), an oncology-focused clinical-stage immunotherapy company, today announced the enrollment of the anal cancer cohort in the […]
Oncolytics Biotech® Begins Enrollment Expansion for GOBLET Anal Cancer Cohort
Successful stage 1 data support expansion, with nearly three times the objective response rate compared to checkpoint inhibitor monotherapy, including complete responses. san diego and Calgary, Alberta, February 14, 2024 /PRNewswire/ — Oncolytic Biotechnology® Inc. (NASDAQ: Oncy) (TSX: ONC), an oncology-focused clinical-stage immunotherapy company, today announced enrollment expansion of the anal cancer cohort of the […]
Oncolytics Biotech Inc. Announces Anal Cancer Cohort of Peraleolep and Atezolizumab Goblet Phase 1/2 Clinical Trial Meets Efficacy Criteria – November 9, 2023, 7:01 a.m. EST
Oncolytics Biotech Inc. announces positive interim results from the Phase 1/2 GOBLET trial evaluating the combination of perolep and atezolizumab in second-line patients with unresectable anal canal squamous cell carcinoma, led by Dirk Arnold, MD. It was announced that it was announced. Director of the Asklepios Oncology Center in Hamburg and principal investigator of the […]
Oncolytics Announces Anal Cancer Cohort of GOBLET Phase 1/2 Study of Peralolep and Atezolizumab Meets Efficacy Success Criteria
Data for the combination of peralolep and atezolizumab exceeds previous controlled trials with an objective response rate of 37.5%, including complete responses. SAN DIEGO and CALGARY, Alberta, Nov. 9, 2023 /PRNewswire/ — Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), an oncology-focused clinical-stage immunotherapy company, today announced that gave a presentation on intermediate therapeutic drugs. Results […]